Research Priorities for Malignant Pleural Organization with Loculation and Failed Drainage

Our plain-English summary of Research Priorities for Malignant Pleural Organization with Loculation and Failed Drainage, by T.A. Tucker, E. Massarelli, L. Destarac, et al (Cells, 2025).

The study

• Authors: T.A. Tucker, E. Massarelli, L. Destarac, S. Idell
• Journal: Cells
• Published: 2025;14(14)
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural effusion (MPE) can lead to pleural organization with loculation and impaired drainage. This condition is becoming increasingly more common due to advancements in cancer therapy and extended patient survival. Factors such as repeated thoracentesis through an indwelling pleural catheter (IPC), intrapleural bleeding, and tumor progression contribute to MPE organization. Loculated MPE causes breathlessness and reduced quality of life, and current therapies, including intrapleural fibrinolytic or enzymatic therapy (IPFT/IET), have limitations in efficacy and safety. Identifying new therapeutic targets is crucial for improving treatment outcomes. Research is needed to understand the role of profibrogenic factors in pleural neoplasia, their regulation, and their impact on different stages of pleural organization. The development of a rabbit model of organizing MPE could provide insights into underlying mechanisms and novel interventions. Comparative studies of pleural tissues and effusions from MPE patients and other forms of pleural organization may reveal valuable information. Cellular and molecular profiling, assessment of biomarkers, and personalized IPFT dosing are potential areas of investigation. Suppression of PAI-1 activity and the role of hyaluronic acid in malignant mesothelioma are also important research directions. Understanding the profibrogenic capacity of pleural mesothelial cells undergoing mesenchymal transition (MesoMT) and identifying key contributors and effectors involved in this process are essential for developing effective treatments for loculated MPE.

In plain English

This article was a perspective, not a new study. The authors stated that no new data were created or analyzed. It concerned malignant pleural effusion (MPE), a build-up of fluid in the chest lining caused by cancer, and how that fluid can organize into walled-off pockets (loculation) that do not drain. Asbestos was not discussed. The authors wrote that how often loculation occurs in MPE is unclear. To their knowledge, no form of the clot-dissolving drugs placed in the chest (intrapleural fibrinolytic therapy, IPFT) is approved by the FDA or any other regulatory body. They reported their own unpublished finding that site inactivated factor VII or TFPI did not clear loculations in a rabbit model, and said they were building a rabbit model of organizing MPE. They proposed research on biomarkers, PAI-1, hyaluronic acid (which earlier work linked to thick fluid in malignant mesothelioma) and changes in pleural lining cells (MesoMT). The authors concluded that new treatment targets urgently need investigation. They noted that preclinical testing simulates but does not recapitulate real clinical circumstances.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Perspective (opinion and research-agenda article); no new data
• Who was studied: No patients or animals were studied for this article; it discussed patients with malignant pleural effusion in general
• Main results:
  • The authors wrote that the incidence of loculation and failed drainage in malignant pleural effusion is unclear and little studied
  • The authors stated that, to their knowledge, no form of intrapleural fibrinolytic therapy is approved by the FDA or any other regulatory body, and that current doses and schedules were chosen empirically
  • The authors reported their own unpublished finding that site inactivated factor VII or TFPI, given into the chest with or without intravenous dosing, did not clear loculations in a rabbit model of tetracycline-induced loculation
  • The authors stated they were not aware of any clinical trials testing anticoagulants placed in the chest for loculated malignant pleural effusion
  • The authors said they were in the process of creating a rabbit model of organizing malignant pleural effusion for testing different forms of fibrinolytic therapy
  • Citing earlier work, the authors noted that high pleural fluid viscosity in malignant mesothelioma may depend partly on high levels of hyaluronic acid, and said its role in loculated effusion in other cancers remains to be studied
  • The authors named myocardin, ZIP kinase, Tuftelin 1 and mTORC2 as contributors to the transition of pleural mesothelial cells (MesoMT) and proposed them as targets for study
• The authors' conclusion: The authors concluded that there is an urgent need to investigate new treatment targets for organization in malignant pleural effusion. They added that biomarker research and personalized approaches could potentially improve outcomes, contingent on successful future clinical trials.
• Limitations the authors state:
  • The authors stated that preclinical (animal) testing simulates but does not recapitulate actual clinical circumstances
  • The authors acknowledged that new fibrinolytic schedules may be testable in clinical trials without precise supporting preclinical data
  • The authors stated that trials comparing one fibrinolytic agent with another may be untenable for logistic and financial reasons

Topics

Medical terms in this study, explained in our Lexicon: Pleural Effusion, Thoracentesis, Indwelling Pleural Catheter, Quality of Life, Molecular Profiling, Biomarker, Hyaluronic Acid, Mesothelioma.

Related studies

• Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial — S. Muruganandan, M. Azzopardi, et al. (2018)
• Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters — M. Azzopardi, R. Thomas, et al. (2016)
• Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage — P. Lange, J. Mortensen, et al. (1988)
• Interventional therapies for malignant pleural effusions: the present and the future — R. Thomas, R. Francis, et al. (2014)
• Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis — M. Yeung, E.W. Loh, et al. (2020)
• Gelatinous pleural effusion in advanced lung adenocarcinoma: a case report — J. Sutton, Y. Grabie, et al. (2025)

Browse more research in Cells, or return to medical research.